Avacincaptad pegol sodium

培阿普特

Report date: 2026/05/07 15:29:48
NME

Base Information

Drug NameAvacincaptad pegol sodium
Drug Alias Name培戈-阿伐普他Anti-C5 aptamerAvacincaptadum pegolumZimuraIzervay +[7] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide aptamer
Mechanisms of ActionComplement C5 inhibitors
TargetsComplement C5
Therapy Area/IndicationsPolypoidal choroidal vasculopathyGeographic AtrophyMacular Degeneration
Global Approved IndicationsGeographic AtrophyMacular Degeneration
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/08/04
Country/TerritoryCzechiaBelgiumCanada +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesArchemix Corp
China Registration ClassN/A

Develop Information

Active CompaniesAstellas Pharma Us IncIveric Bio IncAstellas Pharma Inc +[4] 
Inactive CompaniesOphthotech Co
Active IndicationsGeographic AtrophyMacular Degeneration
Inactive IndicationsPolypoidal choroidal vasculopathy

Other Information

ATC CodeN/A
Related LinksN/A